Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GSK, Merck move combo therapy into Phase 1
December 2015
EDIT CONNECT

SHARING OPTIONS:

LONDON—GlaxoSmithKline and Merck & Co., also known as MSD outside of the United States and Canada, recently began a Phase 1 clinical trial to evaluate GSK’s investigational immunotherapy GSK3174998, a humanized IgG1 anti-OX40 monoclonal antibody, both as a monotherapy and in combination with Merck’s Keytruda. The trial will consist of patients with locally advanced, recurrent or metastatic solid tumors that have progressed after standard treatment. OX40 is a tumor necrosis factor expressed on the surface of activated CD4+ and CD8+ T cells, and OX40 agonism is found to stimulate immune effector and memory functions while also mitigating the immunosuppressive regulatory T cells sometimes found in tumors. For its part, Keytruda helps boost the immune system’s ability to detect and destroy tumor cells by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.